MoonLake Immunotherapeutics (MLTX) Receivables - Other (2021 - 2026)

MoonLake Immunotherapeutics' Receivables - Other history runs 6 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• In Q1 2026, Receivables - Other rose 92.87% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 92.87% YoY), while the FY2025 annual figure was $4.9 million, up 71.2% from the prior year.
• Receivables - Other was $5.8 million for Q1 2026 at MoonLake Immunotherapeutics, up from $4.9 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $5.8 million in Q1 2026 to a low of $217129.0 in Q4 2022.
• Historically, Receivables - Other has averaged $2.1 million across 5 years, with a median of $1.6 million in 2024.
• Biggest YoY gain for Receivables - Other was 386.74% in 2023; the steepest drop was 11.26% in 2023.
• A 5-year view of Receivables - Other shows it stood at $217129.0 in 2022, then jumped by 386.74% to $1.1 million in 2023, then surged by 169.1% to $2.8 million in 2024, then jumped by 71.2% to $4.9 million in 2025, then gained by 18.36% to $5.8 million in 2026.
• The last three Receivables - Other figures came in at $5.8 million (Q1 2026), $4.9 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.